
|Videos|December 20, 2022
Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274
Author(s)Terence Friedlander, MD
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5







































